Source: Markets Insider
Biopharma company Adaptimmune spiked as much as 338% in Monday trading after announcing “partial responses” (PRs) in four tumor indicators. The company’s SPEAR T-cell platform delivered two confirmed PRs in patients with liver cancer and melanoma, according to a Monday statement . The platform also boasted two unconfirmed PRs in patients with gastro-esophageal junction cancer and head and neck cancer. The responses show the platform “is clearly active and can overcome the challenges of treating a range of solid tumors,” CEO Adrian Rawcliffe said. Watch Adaptimmune trade live here . Biopharmaceutical company Adaptimmune rocketed as much as 338% in Monday trading after announcing “partial responses” (PRs) for four tumor indicators. The company’s SPEAR T-cell platform delivered two confirmed PRs in patients with liver cancer and melanoma, according to a Monday statement . The platform also boasted two unconfirmed PRs in patients with gastro-esophageal junction cancer and head and neck cancer.
Leave a Reply